Nagasue N, Yamanoi A, Takemoto Y, Kimoto T, Uchida M, Chang Y C, Taniura H, Kohno H, Nakamura T
Second Department of Surgery, Shimane Medical University, Izumo, Japan.
Br J Surg. 1992 Jul;79(7):667-70. doi: 10.1002/bjs.1800790723.
Nuclear DNA content of hepatocellular carcinoma (HCC) was estimated by flow cytometry after hepatic resection in 91 patients during the past 5 years. There were 53 diploid and 38 aneuploid tumours. Clinicopathological features were compared retrospectively between the patients with diploid and those with aneuploid HCC. DNA ploidy did not show any correlation with age, sex, alcohol abuse, hepatitis B virus, serum alpha-fetoprotein level or underlying liver disease. Histopathologically, the incidence of HCC less than 2 cm in diameter tended to be higher in the diploid group but no difference was seen for large tumours (greater than 5 cm). The grade of tumour differentiation also tended to be higher in this group of small HCC. The ploidy pattern did not influence the rate of capsule or daughter nodule formation, or venous invasion. There were no significant differences in survival rate or in the incidence and time of intrahepatic tumour recurrence between the two groups. This study may indicate that nuclear DNA ploidy is not a particularly predictive factor for the surgical treatment of HCC.
在过去5年中,对91例接受肝切除的肝细胞癌(HCC)患者,通过流式细胞术估计其细胞核DNA含量。其中有53例二倍体肿瘤和38例非整倍体肿瘤。对二倍体HCC患者和非整倍体HCC患者的临床病理特征进行回顾性比较。DNA倍性与年龄、性别、酗酒、乙型肝炎病毒、血清甲胎蛋白水平或潜在肝脏疾病均无相关性。组织病理学检查显示,直径小于2 cm的HCC在二倍体组中的发生率往往较高,但大肿瘤(大于5 cm)未见差异。在这组小HCC中,肿瘤分化程度也往往较高。倍性模式不影响包膜或子结节形成率,也不影响静脉侵犯。两组之间的生存率、肝内肿瘤复发的发生率和时间均无显著差异。本研究可能表明,细胞核DNA倍性并非HCC手术治疗的特别预测因素。